Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Underwriters Exercise Over-allotment Option

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm today said that the underwriters for its initial public offering have exercised their over-allotment option, purchasing an additional 833,750 shares of the firm's common stock for $13.50 per share.

Fluidigm went public last week, selling 5,558,333 shares of common stock at a price of $13.50 per share.

Following the exercise of the over-allotment option, Fluidigm said that its net proceeds from the offering were $78 million.

The South San Francisco, Calif.-based firm said that it estimates $15 million in proceeds from the offering will be used for sales and marketing activities, including adding sales personnel to support commercialization of its products; $12 million will be used for R&D; $4 million will be used for facility improvements and the purchase of manufacturing and other equipment; and $5 million will be used to for repay principal plus accrued interest on promissory notes issued by Fluidigm last month. The balance of the funds will be used for working capital and other general corporate purposes.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.